June 8, 2023: Endocrine Disruption Litigation Has Arrived In their latest article for Carrier Management, Praedicat’s David Loughran and Adam Grossman explore the emergence of endocrine disruption as a major…
read morePraedicat Posts on Litigation
Praedicat Lloyd’s Lab Demo Day 2020 We are excited and proud of our work in the Lab! A tremendous THANK YOU to our mentors and everyone in the Lloyd’s market…
read moreNovember 18th 2020: Praedicat press release on our participation in Lloyd’s Lab Cohort 5 Demo Day We are excited and proud of our work in the Lab! A tremendous THANK…
read morePraedicat CEO Presents at Rand’s Opioid Symposium: There is still time to register for the Rand Corporation’s latest symposium: Opioid Litigation: What’s New and What Does It Mean for Future…
read moreOctober 4th, 2020: In the RIMS Risk Management Monitor article, ‘‘Take-Home COVID-19’ Claims: Preparing for a Second Wave of Coronavirus Litigation’, Praedicat Head of Product and Chief Economist, Dr. David Loughran deliberates…
read moreJuly 27th 2020: Praedicat press release on our COVID-19 Litigation Tracker Praedicat has released updates to our unprecedented Litigation Tracker, which monitors emerging SARS-CoV-2 litigation complaint by complaint. With more…
read moreJune 25th, 2020: Praedicat announces the launch of our unprecedented COVID-19 Litigation Tracker Praedicat is proud to introduce our new Litigation Tracker, which monitors emerging SARS-CoV-2 litigation complaint by complaint.…
read moreMay 9th 2020: In the Bitesize article, Oxbow Partners gives a first glimpse of Praedicat’s COVID-19 scenario modelling solution and litigation tracker, both of which are set to launch later…
read moreApril 29th: In an article published by Insurance ERM, Praedicat scenario tool targets Covid-19 litigation assessments, Robert Reville, Praedicat CEO, discusses the upcoming launch of a suite of tools to…
read moreApril 1st, 2020 – Kate Smith, from A.M. Best Review interviewed Bob Reville, CEO of Praedicat, on the shifting litigation landscape and the recent 4th party litigation on opioids. In…
read more